0.09
-0.0228(-19.37%)
Currency In USD
| Previous Close | 0.12 |
| Open | 0.11 |
| Day High | 0.11 |
| Day Low | 0.06 |
| 52-Week High | 0.52 |
| 52-Week Low | 0.03 |
| Volume | 2.31M |
| Average Volume | 1.12M |
| Market Cap | 6.52M |
| PE | -0.31 |
| EPS | -0.31 |
| Moving Average 50 Days | 0.12 |
| Moving Average 200 Days | 0.23 |
| Change | -0.02 |
If you invested $1000 in AIM ImmunoTech Inc. (AIM) 10 years ago, it would be worth $0.69 as of May 09, 2025 at a share price of $0.095. Whereas If you bought $1000 worth of AIM ImmunoTech Inc. (AIM) shares 5 years ago, it would be worth $41.26 as of May 09, 2025 at a share price of $0.095.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists
GlobeNewswire Inc.
Yesterday at 12:45 PM GMT
OCALA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (OTC Pink: AIMI) (“AIM” or the “Company”) today announced the presentation of clinical trial data involving AIM’s drug Ampligen by Pawel Kalinski, MD, PhD, at th
AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market
GlobeNewswire Inc.
Apr 07, 2025 5:26 PM GMT
OCALA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (“AIM” or the “Company”) (OTC Pink: AIMI) — an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders an
AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal
GlobeNewswire Inc.
Apr 04, 2025 8:45 PM GMT
OCALA, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (“AIM” or the “Company”) (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders
Data not available